医学分子生物学CRISPR基因编辑与社会法规的进步与完善  

CRISPR/Cas Gene Editing in Medical Biology and Progress and Perfection of Social Regulations

作　　者：杨蓉[1] 梁瑜[1] 于秋霞 吴亚君 雷新娟 孙渝婷 王丹[1] 张伟[1] 周鑫[1,2] 李忠光 王李阳[1,3] MengMeng Xu William Isaacs[5] Jianjie Ma 徐学红 Yang Rong(Cell Biology,Genetics and Developmental Biology,College of Life Science,Shaanxi Normal University,Xi’an,710119)

机构地区：[1]陕西师范大学生命科学学院细胞遗传及发育生物学,西安710119 [2]Ohio State University School of Medicine,Columbus [3]BID Medical Center,Harvard Medical School,Boston [4]Duke University Medical Center,Durham [5]Johns Hopkins University School of Medicine,Baltimore,MD21287,USA

出　　处：《医学与社会》2019年第6期33-35,38,共4页Medicine and Society

基　　金：国家自然科学基金面上项目,编号为31571273、31771277、31371256;教育部外事局“海外名师”项目,编号为MS2014SXSF038;教育部中央高校团队项目,编号为#GK20130100/201701005/GERP-17-45;US Maryland SC Research Fund,编号为2009MSCRFE008300;优博基金项目,编号为X2015YB05、X2014YB02

摘　　要：利用CRISPR基因技术体系进行精密编辑,标志着人类攻克遗传疾病在理论上已进入新阶段,临床应用已有了实质性的突破,对促进人类健康和社会的和谐具有重大意义。本文对该技术在临床的应用、社会影响、西方国家对该技术社会伦理道德的界定和法律法规的发展,以及CRISPR精密编辑技术对科研与社会伦理道德范畴的精细化进行了探讨。CRISPR在生殖生物学领域的应用,将导致生物医学领域发生社会发展的重大变革。CRISPR精准基因编辑和干细胞技术的巨大科研前景和商业价值,可能会带来一系列的问题。CRISPR基因精密编辑在生物医学中的应用对社会、对各级医疗机构、医学院校和研究机构均有重要的影响,卫生主管部门应借鉴国际上相关做法,制定科学研究伦理道德的相关政策法规,使中国在医学分子生物学领域作出应有的贡献。We first briefly introduced the current application of CRISPR/Cas gene editing system for diagnostics of human genetic diseases. Promising progress encourages multiple clinic trial on human reproduction system even in human embryo and generated society attention on its ethical and moral issues. The most recent progress on human embryo targeting on HIV/ADIS promotes urgent ethical issue changeling international regulation. Then, CRISPR gene precise editing will generate tremendous effect on reproduction biology. The consequent event would change the situation of moral principle and modernization of the principle would be strongly compensated by this CRISPR technology. Our society should arrange on mastering its future by generating most effective policy and regulation on related moral principle.

关 键 词：精准基因编辑 CRISPR/Cas基因编辑 干细胞 伦理学 

分 类 号：R19-019[医药卫生—卫生事业管理]